Bevacizumab and Retinal Vascular Occlusions

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00347711

Enrollment

Registered

2006-07-04

Start date

2006-06-30

Completion date

2006-06-30

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Edema Macular, Vascular Occlusion

Brief summary

To evaluate the effects of Intravitreal Bevacizumab in macular edema in retinal vascular occlusion.

Interventions

DRUGIntravitreal injection

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to 90 Years

Inclusion criteria

* Vascular occlusion and edema macular diagnosticated by fluorescein angiography and coherent optic tomography

Exclusion criteria

* Previous surgery * Uveitis * Glaucoma

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026